

Jogeshwar Mukherjee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9579505/publications.pdf>

Version: 2024-02-01

133
papers

4,402
citations

136950

32
h-index

123424

61
g-index

138
all docs

138
docs citations

138
times ranked

4939
citing authors

#	ARTICLE	IF	CITATIONS
1	Four-modality imaging of unmedicated subjects with schizophrenia: 18F-fluorodeoxyglucose and 18F-fallypride PET, diffusion tensor imaging, and MRI. <i>Psychiatry Research - Neuroimaging</i> , 2022, 320, 111428.	1.8	1
2	[124I]IBETA: A New A β 2 Plaque Positron Emission Tomography Imaging Agent for Alzheimer's Disease. <i>Molecules</i> , 2022, 27, 4552.	3.8	11
3	Development and evaluation of [125 I]IPPI for Tau imaging in postmortem human Alzheimer's disease brain. <i>Synapse</i> , 2021, 75, e22183.	1.2	10
4	[18F]FDG PET/CT Studies in Transgenic H α lpha-Syn (A53T) Parkinson's Disease Mouse Model of β -Synucleinopathy. <i>Frontiers in Neuroscience</i> , 2021, 15, 676257.	2.8	12
5	Development and evaluation of [18F]Flotaza for A β 2 plaque imaging in postmortem human Alzheimer's disease brain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 46, 128164.	2.2	11
6	Reading abilities and dopamine D2/D3 receptor availability: An inverted U-shaped association in subjects with schizophrenia. <i>Brain and Language</i> , 2021, 223, 105046.	1.6	4
7	[18F]Nifene PET/CT Imaging in Mice: Improved Methods and Preliminary Studies of β -4 β 2* Nicotinic Acetylcholinergic Receptors in Transgenic A53T Mouse Model of β -Synucleinopathy and Post-Mortem Human Parkinson's Disease. <i>Molecules</i> , 2021, 26, 7360.	3.8	14
8	Dopamine receptor density and white matter integrity: 18F-fallypride positron emission tomography and diffusion tensor imaging study in healthy and schizophrenia subjects. <i>Brain Imaging and Behavior</i> , 2020, 14, 736-752.	2.1	11
9	Positive association between cerebral grey matter metabolism and dopamine D ₂ /D ₃ receptor availability in healthy and schizophrenia subjects: An ¹⁸ F-fluorodeoxyglucose and ¹⁸ F-fallypride positron emission tomography study. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 368-382.	2.6	14
10	Development of zirconium-89 PET for imaging of alpha-klotho. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 10, 95-105.	1.0	1
11	Development of fluorescence imaging probes for nicotinic acetylcholine β -4 β 2* receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 371-377.	2.2	6
12	Dual targeting agents for A β 2 plaque/P-glycoprotein and A β 2 plaque/nicotinic acetylcholine β -4 β 2* receptors: potential approaches to facilitate A β 2 plaque removal in Alzheimer's disease brain. <i>Medicinal Chemistry Research</i> , 2018, 27, 1634-1646.	2.4	10
13	D2/D3 dopamine receptor binding with [F-18]fallypride correlates of executive function in medication-naïve patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 192, 442-456.	2.0	14
14	Human brain imaging of nicotinic acetylcholine β -4 β 2* receptors using [¹⁸ F]Nifene: Selectivity, functional activity, toxicity, aging effects, gender effects, and extrathalamic pathways. <i>Journal of Comparative Neurology</i> , 2018, 526, 80-95.	1.6	26
15	[¹⁸ F]Nifene test-retest reproducibility in first-in-human imaging of β -4 β 2* nicotinic acetylcholine receptors. <i>Synapse</i> , 2017, 71, e21981.	1.2	13
16	Brain and Brown Adipose Tissue Metabolism in Transgenic Tg2576 Mice Models of Alzheimer Disease Assessed Using ¹⁸ F-FDG PET Imaging. <i>Molecular Imaging</i> , 2017, 16, 153601211770455.	1.4	22
17	283. D2/D3 Dopamine Receptor Binding with [F-18] Fallypride Correlates of Executive Function in Medication-Naïve Patients with Schizophrenia. <i>Biological Psychiatry</i> , 2017, 81, S116-S117.	1.3	0
18	PET radiotracer development for imaging high-affinity state of dopamine D2 and D3 receptors: Binding studies of fluorine-18 labeled aminotetralins in rodents. <i>Synapse</i> , 2017, 71, e21950.	1.2	4

#	ARTICLE	IF	CITATIONS
19	Human biodistribution and dosimetry of [¹⁸ F]nifene, an α 4 β 2* nicotinic acetylcholine receptor PET tracer. <i>Nuclear Medicine and Biology</i> , 2017, 55, 7-11.	0.6	11
20	79. D2/D3 Dopamine Receptor Binding With [F-18] Fallypride Correlates of Executive Function in Medication-Naive Patients With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2017, 43, S44-S45.	4.3	1
21	Classification of Therapeutic and Experimental Drugs for Brown Adipose Tissue Activation: Potential Treatment Strategies for Diabetes and Obesity. <i>Current Diabetes Reviews</i> , 2016, 12, 414-428.	1.3	28
22	Evaluation of [¹¹ C]TAZA for amyloid β 2 plaque imaging in postmortem human Alzheimer's disease brain region and whole body distribution in rodent PET/CT. <i>Synapse</i> , 2016, 70, 163-176.	1.2	12
23	Comparative assessment of [¹⁸ F]mefway as a serotonin 5-HT _{1A} receptor PET imaging agent across species: Rodents, nonhuman primates, and humans. <i>Journal of Comparative Neurology</i> , 2016, 524, 1457-1471.	1.6	15
24	Synthesis and evaluation of (S)-[¹⁸ F]fisetron in the rat brain as a potential PET imaging agent for serotonin 5-HT ₃ receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1919-1924.	2.2	10
25	Initial Assessment of β 3-Adrenoceptor-Activated Brown Adipose Tissue in Streptozotocin-Induced Type 1 Diabetes Rodent Model Using [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. <i>Molecular Imaging</i> , 2015, 14, 7290.2015.00028.	1.4	7
26	Enhancement of [¹⁸ F]fluorodeoxyglucose metabolism in rat brain frontal cortex using a β 3 adrenoceptor agonist. <i>Synapse</i> , 2015, 69, 96-98.	1.2	17
27	Dopamine D3 receptor binding of [¹⁸ F]fallypride: Evaluation using in vitro and in vivo PET imaging studies. <i>Synapse</i> , 2015, 69, 577-591.	1.2	23
28	¹⁸ F-Fluorodeoxyglucamines: Reductive amination of hydrophilic ¹⁸ F-fluoro-2-deoxyglucose with lipophilic amines for the development of potential PET imaging agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2902-2906.	2.2	3
29	Preliminary evaluation of β 3-adrenoceptor agonist-induced ¹⁸ F-FDG metabolic activity of brown adipose tissue in obese Zucker rat. <i>Nuclear Medicine and Biology</i> , 2015, 42, 691-694.	0.6	15
30	Synthesis and evaluation of mefway analogs as ligands for serotonin 5HT _{1A} receptors. <i>Medicinal Chemistry Research</i> , 2015, 24, 1480-1486.	2.4	1
31	First-in-Human Evaluation of [¹⁸ F]mefway, a PET Radioligand Specific to Serotonin-1A Receptors. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1973-1979.	5.0	19
32	[¹⁸ F]fluorodeoxyglycosylamines: Maillard reaction of [¹⁸ F]fluorodeoxyglucose with biological amines. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 86-91.	1.0	11
33	2-deoxy-2-[¹⁸ F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis. <i>Nature Medicine</i> , 2014, 20, 215-219.	30.7	159
34	Adrenergic pathway activation enhances brown adipose tissue metabolism: A [¹⁸ F]FDG PET/CT study in mice. <i>Nuclear Medicine and Biology</i> , 2014, 41, 10-16.	0.6	57
35	Imaging Pancreas in Healthy and Diabetic Rodent Model Using [¹⁸ F]Fallypride Positron Emission Tomography/Computed Tomography. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 640-643.	4.4	12
36	Spinal cord dopamine D2/D3 receptors: in vivo and ex vivo imaging in the rat using [¹⁸ F]fallypride. <i>Nuclear Medicine and Biology</i> , 2014, 41, 841-847.	0.6	7

#	ARTICLE	IF	CITATIONS
37	124I-Epidepride: A PET radiotracer for extended imaging of dopamine D2/D3 receptors. <i>Nuclear Medicine and Biology</i> , 2014, 41, 426-431.	0.6	12
38	D ₂ receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. <i>CNS Spectrums</i> , 2014, 19, 176-181.	1.2	20
39	Multimodality Imaging Probe for Positron Emission Tomography and Fluorescence Imaging Studies. <i>Molecular Imaging</i> , 2014, 13, 7290.2014.00005.	1.4	11
40	Targeting histone deacetylase in lung cancer for early diagnosis: (18)F-FAHA PET/CT imaging of NNK-treated A/J mice model. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 324-32.	1.0	5
41	Synthesis and evaluation of 2-(18)F-fluoro-5-iodo-3-[2-(S)-3,4-dehydropyrrolinylmethoxy]pyridine ((18)F-Niofene) as a potential imaging agent for nicotinic $\alpha 4 \beta 2$ receptors. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 354-64.	1.0	4
42	Initial in vivo PET imaging of 5-HT _{1A} receptors with 3-[(18)F]mefway. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 483-9.	1.0	2
43	Multimodality imaging probe for positron emission tomography and fluorescence imaging studies. <i>Molecular Imaging</i> , 2014, 13, 1-7.	1.4	4
44	Evaluation of serotonin 5-HT _{1A} receptors in rodent models using [¹⁸ F]mefway PET. <i>Synapse</i> , 2013, 67, 596-608.	1.2	21
45	Evaluation of [18F]Mefway Biodistribution and Dosimetry Based on Whole-Body PET Imaging of Mice. <i>Molecular Imaging and Biology</i> , 2013, 15, 222-229.	2.6	20
46	Evaluation of [18F]Nifene biodistribution and dosimetry based on whole-body PET imaging of mice. <i>Nuclear Medicine and Biology</i> , 2013, 40, 289-294.	0.6	22
47	Synthesis and biological evaluation of 18F-Norfallypride in the rodent brain using PET imaging. <i>Nuclear Medicine and Biology</i> , 2013, 40, 697-704.	0.6	0
48	Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E2239-48.	7.1	71
49	A progressive translational mouse model of human valosin α -containing protein disease: The <i>VCP</i> ^{R155H/+} mouse. <i>Muscle and Nerve</i> , 2013, 47, 260-270.	2.2	58
50	Targeting presynaptic norepinephrine transporter in brown adipose tissue: A novel imaging approach and potential treatment for diabetes and obesity. <i>Synapse</i> , 2013, 67, 79-93.	1.2	22
51	5-HT _{1A} sex based differences in Bmax, in vivo KD, and BPND in the nonhuman primate. <i>NeuroImage</i> , 2013, 77, 125-132.	4.2	9
52	The effects of lobeline on $\alpha 4 \beta 2$ nicotinic acetylcholine receptor binding and uptake of [18F]nifene in rats. <i>Journal of Neuroscience Methods</i> , 2013, 214, 163-169.	2.5	11
53	Nicotinic $\alpha 4 \beta 2$ receptor imaging agents. Part IV. Synthesis and Biological Evaluation of 3-(2-(S)-3,4-dehydropyrrolinyl methoxy)-5-(3- ¹⁸ F-Fluoropropyl)pyridine (18F-Nifrolene) using PET. <i>Nuclear Medicine and Biology</i> , 2013, 40, 117-125.	0.6	13
54	Measuring $\alpha 4 \beta 2$ — Nicotinic Acetylcholine Receptor Density in Vivo with [18F]nifene PET in the Nonhuman Primate. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1806-1814.	4.3	15

#	ARTICLE	IF	CITATIONS
55	PET imaging of acetylcholinesterase inhibitor-induced effects on $\alpha 4 \beta 2$ nicotinic acetylcholine receptor binding. <i>Synapse</i> , 2013, 67, 882-886.	1.2	11
56	Development of novel approach to diagnostic imaging of lung cancer with ^{18}F -Nifene PET/CT using A/J Mice treated with NNK. <i>Journal of Cancer Research & Therapy</i> , 2013, 1, 128-137.	0.1	9
57	Measurement of 5-HT_{1A} Receptor Density and <i>in-vivo</i> Binding Parameters of [^{18}F]mefway in the Nonhuman Primate. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1546-1558.	4.3	14
58	PET Imaging of $\alpha 4 \beta 2$ * Nicotinic Acetylcholine Receptors: Quantitative Analysis of ^{18}F -Nifene Kinetics in the Nonhuman Primate. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1471-1480.	5.0	26
59	Ketoconazole-Associated Preferential Increase in Dopamine D2 Receptor Occupancy in Striatum Compared to Pituitary In Vivo. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 110-113.	1.4	5
60	Modulating Blood-Brain Barrier Permeability and Treatment-Resistant Psychiatric Illness: Is Pituitary Neuroimaging a New Frontier?. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2012, 10, 182-184.	0.2	0
61	Synthesis and evaluation of 3- ^{123}I -iodo-5-[2-(S)-3-pyrrolinylmethoxy]-pyridine (niodene) as a potential nicotinic $\alpha 4 \beta 2$ receptor imaging agent. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 7610-7614.	2.2	7
62	Nicotinic acetylcholine receptors in rat forebrain that bind ^{18}F -nifene: Relating PET imaging, autoradiography, and behavior. <i>Synapse</i> , 2012, 66, 418-434.	1.2	31
63	The Homozygote VCP/R155H Mouse Model Exhibits Accelerated Human VCP-Associated Disease Pathology. <i>PLoS ONE</i> , 2012, 7, e46308.	2.5	56
64	An in vivo comparison of cis- and trans-[^{18}F]mefway in the nonhuman primate. <i>Nuclear Medicine and Biology</i> , 2011, 38, 925-932.	0.6	16
65	Nicotinic $\alpha 4 \beta 2$ receptor imaging agents. Part III. Synthesis and biological evaluation of 3-(2-(S)-azetidylmethoxy)-5-(3- ^{18}F -fluoropropyl)pyridine (^{18}F -nifzetidine). <i>Nuclear Medicine and Biology</i> , 2011, 38, 1183-1192.	0.6	14
66	Quantitative assessment of brown adipose tissue metabolic activity and volume using ^{18}F -FDG PET/CT and ^{123}I -adrenergic receptor activation. <i>EJNMMI Research</i> , 2011, 1, 30.	2.5	73
67	Evaluation of ^{18}F -nifene binding to $\alpha 4 \beta 2$ nicotinic receptors in the rat brain using microPET imaging. <i>EJNMMI Research</i> , 2011, 1, 6.	2.5	22
68	The Multiple Faces of Valosin-Containing Protein-Associated Diseases: Inclusion Body Myopathy with Paget's Disease of Bone, Frontotemporal Dementia, and Amyotrophic Lateral Sclerosis. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 522-531.	2.3	126
69	In vivo kinetics of [^{18}F]MEFWAY: A comparison with [^{11}C]WAY100635 and [^{18}F]MPPF in the nonhuman primate. <i>Synapse</i> , 2011, 65, 592-600.	1.2	36
70	Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [^{18}F]fallypride and [^{18}F]desmethoxyfallypride. <i>Synapse</i> , 2011, 65, 778-787.	1.2	33
71	Specific $\alpha 4 \beta 2$ nicotinic acetylcholine receptor binding of [^{18}F]nifene in the rhesus monkey. <i>Synapse</i> , 2011, 65, 1309-1318.	1.2	33
72	^{18}F -Fallypride PET of Pancreatic Islets: In Vitro and In Vivo Rodent Studies. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1125-1132.	5.0	20

#	ARTICLE	IF	CITATIONS
73	(¹⁸ F)MPP3) as a potential PET imaging agent for norepinephrine transporter. Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 53, 172-177.	1.0	1
74	Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: In vivo imaging with [¹⁸ F]fallypride. Movement Disorders, 2010, 25, 2777-2784.	3.9	136
75	High-Affinity Dopamine D ₂ /D ₃ PET Radioligands ¹⁸ F-Fallypride and ¹¹ C-FLB457: A Comparison of Kinetics in Extrastriatal Regions Using a Multiple-Injection Protocol. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 994-1007.	4.3	52
76	VCP Associated Inclusion Body Myopathy and Paget Disease of Bone Knock-In Mouse Model Exhibits Tissue Pathology Typical of Human Disease. PLoS ONE, 2010, 5, e13183.	2.5	109
77	Performance evaluation of an Inveon PET preclinical scanner. Physics in Medicine and Biology, 2009, 54, 2885-2899.	3.0	150
78	Striatal Dopamine D ₂ /D ₃ Receptor Availability Is Reduced in Methamphetamine Dependence and Is Linked to Impulsivity. Journal of Neuroscience, 2009, 29, 14734-14740.	3.6	330
79	¹¹ C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas. Molecular Imaging and Biology, 2008, 10, 1-18.	2.6	210
80	[¹¹ C]Cyclopropyl-FLB 457: A PET radioligand for low densities of dopamine D2 receptors. Bioorganic and Medicinal Chemistry, 2008, 16, 6467-6473.	3.0	7
81	Radiotracers for a multi-target approach to the diagnosis of Alzheimer's disease. Journal of Labelled Compounds and Radiopharmaceuticals, 2007, 50, 375-379.	1.0	5
82	Effect of acetylcholinesterase inhibitors on the binding of nicotinic $\alpha 4\beta 2$ receptor PET radiotracer, ¹⁸ F-nifene: A measure of acetylcholine competition. Synapse, 2007, 61, 29-36.	1.2	28
83	D2/D3 dopamine receptor binding with [¹⁸ F]fallypride in thalamus and cortex of patients with schizophrenia. Schizophrenia Research, 2006, 85, 232-244.	2.0	128
84	Nicotinic $\alpha 4\beta 2$ receptor imaging agents. Nuclear Medicine and Biology, 2006, 33, 295-304.	0.6	56
85	Positron autoradiography for intravascular imaging: feasibility evaluation. Physics in Medicine and Biology, 2006, 51, 963-979.	3.0	12
86	Synthesis and biologic evaluation of a novel serotonin 5-HT1A receptor radioligand, ¹⁸ F-labeled mefway, in rodents and imaging by PET in a nonhuman primate. Journal of Nuclear Medicine, 2006, 47, 1697-706.	5.0	54
87	Moderate-Level Prenatal Alcohol Exposure Alters Striatal Dopamine System Function in Rhesus Monkeys. Alcoholism: Clinical and Experimental Research, 2005, 29, 1685-1697.	2.4	45
88	Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, ¹⁸ F-fallypride in extrastriatal brain regions in non-human primates using PET. Brain Research, 2005, 1032, 77-84.	2.2	57
89	Functional imaging of a large demyelinating lesion. Journal of Clinical Neuroscience, 2005, 12, 176-178.	1.5	27
90	Methodological development of dynamic dopamine release using [¹⁸ F]desmethoxyfallypride. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S612-S612.	4.3	0

#	ARTICLE	IF	CITATIONS
91	Synthesis and evaluation of nicotine alpha4beta2 receptor radioligand, 5-(3'-18F-fluoropropyl)-3-(2-(S)-pyrrolidinylmethoxy)pyridine, in rodents and PET in nonhuman primate. Journal of Nuclear Medicine, 2005, 46, 130-40.	5.0	25
92	Radiopharmaceuticals for Imaging the Brain. , 2004, , 89-101.		0
93	Measuring the in Vivo Binding Parameters of [18F]-Fallypride in Monkeys Using a PET Multiple-Injection Protocol. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 309-322.	4.3	54
94	Prenatal stress, moderate fetal alcohol, and dopamine system function in rhesus monkeys. Neurotoxicology and Teratology, 2004, 26, 169-178.	2.4	44
95	Binding characteristics of high-affinity dopamine D2/D3 receptor agonists, 11C-PPHT and 11C-ZYY-339 in rodents and imaging in non-human primates by PET. Synapse, 2004, 54, 83-91.	1.2	21
96	11C-Fallypride: radiosynthesis and preliminary evaluation of a novel dopamine D2/D3 receptor PET radiotracer in non-human primate brain. Bioorganic and Medicinal Chemistry, 2004, 12, 95-102.	3.0	31
97	Synthesis and biological evaluation of the binding of dopamine D2/D3 receptor agonist,		

#	ARTICLE	IF	CITATIONS
109	Evaluation of the binding of the radiolabeled antidepressant drug, 18F-fluoxetine in the rodent brain: an in vitro and in vivo study. <i>Nuclear Medicine and Biology</i> , 1998, 25, 605-610.	0.6	38
110	Image reconstruction for dynamic PET based on low-order approximation and restoration of the sinogram. <i>IEEE Transactions on Medical Imaging</i> , 1997, 16, 738-749.	8.9	49
111	Evaluation of monoamine oxidase B inhibition by fluoxetine (Prozac): An in vitro and in vivo study. <i>European Journal of Pharmacology</i> , 1997, 337, 111-114.	3.5	18
112	Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, 18F-fallypride in nonhuman primates using positron emission tomography. <i>Synapse</i> , 1997, 27, 1-13.	1.2	76
113	Synthesis, radiosynthesis, and biological evaluation of fluorinated thienylcyclohexyl piperidine derivatives as potential radiotracers for the NMDA receptor-linked calcium ionophore. <i>Nuclear Medicine and Biology</i> , 1996, 23, 315-324.	0.6	20
114	Fluorinated benzazepines: 1. Synthesis, radiosynthesis and biological evaluation of a series of substituted benzazepines as potential radiotracers for positron emission tomographic studies of dopamine D-1 receptors. <i>Nuclear Medicine and Biology</i> , 1996, 23, 793-805.	0.6	9
115	18F-desmethoxyfallypride: A fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for pet imaging studies of dopamine D2 receptors. <i>Life Sciences</i> , 1996, 59, 669-678.	4.3	41
116	Fluorinated benzamide neurolepticsâ€”III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. <i>Nuclear Medicine and Biology</i> , 1995, 22, 283-296.	0.6	206
117	Development of Fluorine-18 Radiopharmaceuticals for Dopamine Neuroreceptors. , 1995, , 265-275.		0
118	Radionuclide Probes for Tissue Damage. <i>Annals of the New York Academy of Sciences</i> , 1994, 720, 181-191.	3.8	8
119	Radiosynthesis of [F-18]fluoxetine as a potential radiotracer for serotonin reuptake sites. <i>Applied Radiation and Isotopes</i> , 1993, 44, 835-842.	1.5	34
120	Fluorine-18 labelled substituted benzazepines as potential radiotracers for imaging dopamine D1 receptors by positron emission tomography. <i>European Journal of Pharmacology</i> , 1993, 243, 287-290.	3.5	2
121	Fluorinated benzamide neurolepticsâ€”2. Synthesis and radiosynthesis of (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-3-substituted-2-methoxybenzamides. <i>International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes</i> , 1991, 42, 713-721.	0.5	12
122	Use of Diethylaminosulfur Trifluoride in an Efficient Synthesis of		

#	ARTICLE	IF	CITATIONS
127	Radiobrominated m-tyrosine analog as potential CNS L-dopa pet tracer. Biochemical and Biophysical Research Communications, 1988, 150, 1027-1031.	2.1	27
128	Nitrogen-15 NMR studies of the complex of carbonic anhydrase with the novel carbonyl hydration substrate pyruvamide. Evidence for the coordination of the deprotonated amide group to the active site zinc. Journal of the American Chemical Society, 1987, 109, 7232-7233.	13.7	13
129	Interaction of the unique competitive inhibitor imidazole and related compounds with the active site metal of carbonic anhydrase: linkage between pH effects on the inhibitor binding affinity and pH effects on the visible spectra of inhibitor complexes with the cobalt-substituted enzyme. Biochemistry, 1987, 26, 7057-7063.	2.5	11
130	Interaction of amide inhibitors with the active site of carbonic anhydrase: metal-induced deprotonation of the bound amide group is indicated by slow binding kinetics, by visible spectra of complexes with cobalt enzyme, and by pH effects on binding affinity. Biochemistry, 1987, 26, 5672-5679.	2.5	24
131	Molecular Basis for Catalytic Activity Changes in Active-Site-Modified Carbonic Anhydrases: A13C Magnetic Resonance View. Annals of the New York Academy of Sciences, 1984, 429, 114-128.	3.8	6
132	Kinetics and mechanism of the oxidation of primary alcohols by N-bromoacetamide in acid medium. Journal of Organic Chemistry, 1981, 46, 2323-2326.	3.2	37
133	Kinetics and mechanism of the oxidation of substituted benzyl alcohols by sodium N-chlorobenzenesulphonamide. Journal of the Chemical Society Perkin Transactions II, 1980, , 676.	0.9	3